乳腺癌
BRCA2蛋白
癌症
突变
等位基因
遗传学
生物
家族史
基因
癌症研究
肿瘤科
医学
内科学
种系突变
标识
DOI:10.1136/jmg.2004.020446
摘要
Breast cancer is a leading cause of cancer deaths among women, and is expected to claim the lives of nearly 40 000 individuals in the USA each year (American Cancer Society Breast Cancer Facts and Figures 2003–2004 ). Only 5–10% of breast cancers are associated with mutations in the susceptibility genes BRCA1 and BRCA2 . However, in cases associated with strong family history, mutation rates are higher, ranging from 16% to 26% for BRCA1 1–3 and from 7% to 13% for BRCA2 .2,3 However, many breast cancer patients with strong family histories have no obvious mutations in BRCA1 /2. While there is an active search for other breast cancer susceptibility genes, it is possible that the true contributions of BRCA1 and BRCA2 to early onset breast cancer have been underestimated. Indeed, one study has shown that only 63% of breast cancer families linked to BRCA1 are associated with detectable mutations in BRCA1 .4 Several reasons for this discrepancy are possible. For example, mutations in BRCA1 promoter sequences might be undetectable by current detection techniques. Additionally, inherited genomic rearrangements that inactivate BRCA1 and BRCA2 but cannot be detected by conventional polymerase chain reaction (PCR) based assays have been reported.5,6,7,8,9,10 Finally, it is possible that some genetic variants previously dismissed as “unclassified variants” or “polymorphisms” may have hitherto underappreciated effects on protein synthesis or function.
Most studies of BRCA1 and BRCA2 associated breast cancers have focused on white populations, yet several observations suggest that there might be a genetic component to breast cancer susceptibility in families of African ancestry.11 Breast cancer is less common in African populations than in other populations but, when it does occur, it is characterised by an early age of onset and a higher mortality.12–14 Additionally, …
科研通智能强力驱动
Strongly Powered by AbleSci AI